yeah I also thought that, perhaps it is in the numbers of their modelling somewhere but it didn't jump out at me... I.e. what would their valuation be if the trial is a success?
they mention expecting a capital raise next year but without a view on the price they expect (assuming good results in trial) then I don't see how a capital raise can be taken into account...
Ann: CEO presentation to Broker Meets Biotech - Perth, page-62
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
